|
Discovery | Pre-Clinical | Phase I | Phase II | Phase III | Manufacturing | Funding | Intellectual Property | Regulatory | EB Programs
We understand the challenges emerging biotech companies face in the quest to push the next generation of drugs to market. This is why we have developed our EB Grant programs that we run on regular basis in different regions of the world. These programs allow grant recipients receive free products and services.
Apply to our Advance Biotech Grant Program Today!
We are hosting our 8th edition, open for Taiwan biotech companies, to help you accelerate to clinic faster.
Apply now for a chance to win free process solution products and services; and/or process development support.
Apply to our Advance Biotech Grant Program Today!
We are hosting our 7th edition, open for China biotech companies, to help you accelerate to clinic faster.
Apply now for a chance to win free process solution products and services; and/or process development support.
Our 2019 Advance Biotech Grant Program for North America
We have hosted our 2019 Advance Biotech Grant Program for North American biotech companies, to help you accelerate to clinic faster.
The three grant recipients are:
Read the Grant winner announcement
Our 2018 Advance Biotech Grant Program for Europe
We have hosted our 2018 Advance Biotech Grant Program, the 5th edition, for European* biotech companies, to help you accelerate to clinic faster.
Recipients
Read the Grant winner announcement
[*Netherlands, Belgium, Switzerland, United Kingdom, Ireland, France, Germany, Denmark, Finland, Norway, Austria, Spain, Sweden]
Recipients
Recipients received between €25,000 and €100,000 in technologies and services to accelerate therapeutics to market. View Press Release.
Recipients
Each grant recipient received 280,000 CNY in technologies and services.
Recipient
NGM was awarded $89K in products and services. View Announcement.
If you want to be contacted regarding our next Emerging Biotech Grant Program, please leave your details and we will contact you.
Advance Biotech Grant Program – Accelerating Therapeutic Development in Life Science
The Life Science business of MilliporeSigma is expanding its commitment to the global biotech community with its Advance Biotech Grant Program. Through the newly expanded grant program, every six months, three recipients around the globe will be awarded a total of €200,000 in free services and products to address their process development challenges. In total, six companies will benefit from the Advance Biotech Grant Program each year. Press Release
Bringing your molecule to market. As part of our commitment to meet the needs of the life science community, we’ve developed several programs that recognize stand-out emerging biotech companies. These programs are designed to support biotech start-ups and medium sized companies in solving their current bioprocess development challenges to bring the next generation of molecules to market.
Learn more about the advantages to work with one source on your mAb, linker/ payload supplies and conjugation services.
Review the current dynamics in the RNA therapeutics/vaccines market with a focus on process development and manufacturing strategies.
Learn more on points to consider for successful tech transfers with a focus on cGMP training requirements.
Establishing an open dialog within the biotech community....
A report from the The Economist Intelligence Unit sponsored by MilliporeSigma.
This paper, which incorporates the results of a survey of 254 pharmaceutical executives from around the world and a range of interviews with industry experts, explores in detail global pharmaceutical companies' growth strategies and their plans for managing the associated risks.
Research. Development. Production.
We are a leading supplier to the global Life Science industry: solutions and services for research, development and production of biotechnology and pharmaceutical drug therapies.
